These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19846140)

  • 21. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
    Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
    Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study.
    Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
    PLoS One; 2013; 8(11):e81484. PubMed ID: 24312307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
    Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
    Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
    Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
    Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of enhancer of zesle homolog 2 and phosphatase and tension homolog and its clinicopathological significance in benign and malignant lesion of gallbladder].
    Liu DC; Yang ZL; Yang LP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):618-22. PubMed ID: 18667776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
    Ha SY; Kim SH
    Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
    Wagener N; Macher-Goeppinger S; Pritsch M; Hüsing J; Hoppe-Seyler K; Schirmacher P; Pfitzenmaier J; Haferkamp A; Hoppe-Seyler F; Hohenfellner M
    BMC Cancer; 2010 Oct; 10():524. PubMed ID: 20920340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
    Choi JH; Song YS; Yoon JS; Song KW; Lee YY
    APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
    Ougolkov AV; Bilim VN; Billadeau DD
    Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
    Collett K; Eide GE; Arnes J; Stefansson IM; Eide J; Braaten A; Aas T; Otte AP; Akslen LA
    Clin Cancer Res; 2006 Feb; 12(4):1168-74. PubMed ID: 16489070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
    van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
    Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.
    Holland D; Hoppe-Seyler K; Schuller B; Lohrey C; Maroldt J; Dürst M; Hoppe-Seyler F
    Cancer Res; 2008 Dec; 68(23):9964-72. PubMed ID: 19047178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.
    Avissar-Whiting M; Koestler DC; Houseman EA; Christensen BC; Kelsey KT; Marsit CJ
    Epigenetics; 2011 Jun; 6(6):703-9. PubMed ID: 21610323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
    Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
    Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma.
    Kim JY; Lee SH; Moon KC; Kwak C; Kim HH; Keam B; Kim TM; Heo DS
    J Urol; 2015 Oct; 194(4):1112-9. PubMed ID: 25997916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
    Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y
    Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.
    Yoon KA; Gil HJ; Han J; Park J; Lee JS
    J Thorac Oncol; 2010 Jan; 5(1):10-6. PubMed ID: 19901851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
    Wang H; Wang M; Lian G; Wu D
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):99-102. PubMed ID: 23353165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.